SLC18A2 and thanatophoric dysplasia: Indeed, VMAT-2 inhibitors are used to treat tardive dyskinesia (TD)—a condition caused by chronic dopamine receptor blockade and a presumed consequent upregulation of D2 receptors and altered synaptic plasticity.